Arbutus is also exiting its corporate headquarters in Pennsylvania and will terminate all in-house scientific research. The ...

Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced its financial results for the fourth quarter and fiscal year 2024, ...

Arbutus Biopharma restructures to cut costs & focus on Hepatitis B drug imdusiran. Read more about ABUS stock here.

The restructuring is only the latest round of layoffs to hit Arbutus after the company shed 40% of its staff and cut back on ...

Along with its Q4 2024 financials on Thursday, antiviral developer Arbutus Biopharma (NASDAQ:ABUS) announced plans to reduce ...

The clinical-stage biopharmaceutical company said its board approved a workforce reduction of 57%, bringing its employee count down to 19. It also decided to exit its corporate headquarters in ...

LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation ...

Novo is paying up to $1 billion for a “non-incretin” medicine that might boost Wegovy’s effects. Elsewhere, Arbutus laid off ...

Feb. 25, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease ...

Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation scheduled for September 202 ...